Alnylam Pharmaceuticals Inc (DUL.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 10:32AM CEST. Market open.
| Previous close | 132.65 |
| Open | 133.05 |
| Bid | 133.35 x 100000 |
| Ask | 135.25 x 50000 |
| Day's range | 133.05 - 133.25 |
| 52-week range | 131.55 - 195.80 |
| Volume | |
| Avg. volume | 7 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksAlnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
CAMBRIDGE, Mass., April 18, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.
ZacksWhy Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
© 2024 Yahoo. All rights reserved.